Fresenius FRE.DE
What does Fresenius do?
Fresenius is an internationally active healthcare group headquartered in Bad Homburg, Germany. The company mainly cares for severely and chronically ill patients. Its business is organized into two operating segments: Fresenius Kabi and Fresenius Helios.
Fresenius Kabi supplies intravenously administered generics, infusion solutions, clinical nutrition, biosimilars and medical technology such as infusion pumps and disposable products. Its customers are primarily hospitals and healthcare systems. Fresenius Helios operates hospitals in Germany and Spain and is financed mainly by reimbursements from payers such as health insurers. Competitively, Kabi is one of the large providers of infusion and nutrition therapy, with a broad product portfolio and global production. Helios is one of the largest private hospital operators in Europe and competes with other private, public and non-profit operators.
Score profile
Rank vs. Medical Care Facilities (21 companies). 10 = top of the group, 5 = middle. Calculated from the metrics below, without AI.
Metrics compared with the industry
On profitability and quality, Fresenius ranks below average in the group Medical Care Facilities (3.9/10). On growth, the company ranks in the middle in the group Medical Care Facilities (4.8/10). On valuation (higher = cheaper), the stock ranks in the middle in the group Medical Care Facilities (5.7/10). On financial strength, Fresenius ranks in the middle in the group Medical Care Facilities (4.7/10).
| Metric | Stock | Group median | Ranking |
|---|---|---|---|
| Forward P/E | 13.7x | 16.2x | better than 71 % |
| Trailing P/E | 19.0x | 19.7x | better than 53 % |
| PEG ratio | 1.0x | 1.4x | better than 74 % |
| EV/EBITDA | 13.1x | 12.3x | better than 38 % |
| Price/sales | 1.3x | 1.3x | better than 48 % |
| Price/book | 1.5x | 3.2x | better than 92 % |
| Revenue growth | 5.9% | 6.5% | better than 45 % |
| Earnings growth | 6.5% | 6.5% | better than 50 % |
| Gross margin | 26.0% | 29.9% | better than 31 % |
| Operating margin | 9.9% | 10.1% | better than 45 % |
| Net margin | 6.6% | 6.6% | better than 50 % |
| Return on equity | 8.3% | 15.4% | better than 31 % |
| Debt/equity | 57.0% | 78.7% | better than 60 % |
| Current ratio | 1.5x | 1.4x | better than 74 % |
| Free cash flow yield | 1.2% | 3.8% | better than 7 % |
| Dividend yield | 2.0% | 0.6% | – |
| Payout ratio | 37.2% | 12.5% | – |
| Beta | 0.77 | 0.77 | – |
Valuation: what is Fresenius worth?
Two valuation approaches – a discounted cash flow model and a valuation at the industry’s median multiples – give Fresenius a model range of 49.05 EUR to 63.41 EUR per share.
14 analysts, average rating “Strong buy”, average price target 57.73 EUR (+7.7%).
The full DCF matrix, the reverse DCF (what growth the price implies) and scenarios are part of the Pro analysis.
What the business depends on
- Demand for infusion therapies, pharmaceuticals and clinical nutrition grows with the number of chronically and severely ill patients.
- Hospital utilization and the reimbursement rates set by payers largely determine revenue and earnings in the hospital business.
- Efficient production, stable supply chains and a broad portfolio of generics and biosimilars support margins in the pharmaceuticals business.
Risks
- Healthcare policy interventions affecting reimbursement, hospital funding and price regulation can weigh on earnings over the long term.
- Staff shortages and rising personnel and energy costs put margin pressure on hospital operations.
- Production outages, quality defects or supply bottlenecks in sterile drugs can hurt revenue and reputation and trigger regulatory proceedings.
What to look for with Fresenius
The operating margin by segment is particularly informative because it shows how well Kabi and Helios each absorb cost, price and reimbursement pressure.